Group 1 - The company Shanghai Aladdin Biochemical Technology Co., Ltd. has undergone a share transfer due to the dissolution and liquidation of its employee stock ownership platform, Shanghai Jingzhen Cultural and Artistic Development Center (Limited Partnership), which held 7,381,190 shares, accounting for 2.22% of the company's total share capital [1] - The share transfer was completed through a non-trading transfer method, with the shares registered to the partners of Jingzhen Cultural on November 18, 2025 [1][2] - The company confirms that the non-trading transfer will not lead to any change in control or affect the governance structure and daily operations of the company [2][3] Group 2 - Company directors, supervisors, and senior management will continue to adhere to commitments made in the company's prospectus, including restrictions on share transfers during their tenure and for six months post-departure [2] - After the non-trading transfer, the partners of Jingzhen Cultural are prohibited from reducing their holdings within six months and must comply with relevant regulations regarding major shareholder reductions [3] - The new shareholders will have specific limits on share reductions, including a maximum of 1% of total shares through centralized bidding and 2% through block trading within any consecutive 90-day period [3]

天眼查App显示，近日，维诺生化科技（青岛）有限公司成立，法定代表人为孙冰茹，注册资本20万人 民币，经营范围为一般项目：医学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、技术 转让、技术推广；技术进出口；货物进出口；信息咨询服务（不含许可类信息咨询服务）；炼油、化工 生产专用设备销售；充电桩销售；通信设备销售；特种设备销售；智能仪器仪表销售；工业互联网数据 服务；采购代理服务；进出口代理；国际货物运输代理；国内贸易代理；贸易经纪；机械设备租赁；信 息系统运行维护服务；化工产品销售（不含许可类化工产品）；工程管理服务；站用加氢及储氢设施销 售；储能技术服务；太阳能热利用装备销售；太阳能热发电装备销售；生物质能技术服务；电池销售； 气体、液体分离及纯净设备销售；气体压缩机械销售；电池零配件销售；智能输配电及控制设备销售； 机械设备销售；机械电气设备销售；汽车零配件批发。（除依法须经批准的项目外，凭营业执照依法自 主开展经营活动）。 ...

Core Viewpoint - Aladdin's stock price increased by 4.21% to 12.87 yuan as of October 30, 2025, with a trading volume of 171,200 shares and a turnover of 221 million yuan [1] Trading Information Summary - On October 30, 2025, the net outflow of main funds was 19.755 million yuan, accounting for 8.93% of the total turnover; retail investors had a net inflow of 18.9297 million yuan, representing 8.56% of the total turnover [2] Shareholder Changes - As of September 30, 2025, the number of shareholders decreased to 11,600, a reduction of 894, or 7.17% from June 30, 2025; the average number of shares held per account increased from 26,700 to 28,700, with an average market value of 374,400 yuan [3] Financial Performance Highlights - Aladdin's Q3 2025 report indicated a total revenue of 444.4 million yuan for the first three quarters, a year-on-year increase of 17.59%; net profit attributable to shareholders was 57.76 million yuan, down 20.41% year-on-year; Q3 alone saw a revenue of 169 million yuan, up 21.26% year-on-year, and a net profit of 29.30 million yuan, up 15.8% year-on-year [4][6] Company Announcements - Aladdin plans to acquire a 55.97% stake in Kasma Technology through a transaction valued at 133.16 million yuan [5] Key Financial Data - For Q3 2025, the net cash flow from operating activities was 159 million yuan, a significant increase of 142.25% year-on-year, primarily due to the inclusion of Kasma Holdings in the consolidated financial statements [6][7] - Total assets as of September 30, 2025, reached 2.58 billion yuan, a 45.13% increase from the end of the previous year, largely due to the acquisition of Kasma Holdings [7] Shareholder Information - The top ten shareholders include Xu Jiuzhen with 27.72% and Zhao Liping with 14.85% of shares; Xu and Zhao are married, and their company, Shanghai Shichuang Supply Chain Co., Ltd., is controlled by them [8][9]

Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Shanghai Aladdin Biochemical Technology Co., Ltd, specifically the employee shareholding platform, Jingzhen Culture, which has reduced its holdings in the company. Group 1: Shareholder Holding Situation - Before the reduction plan, Jingzhen Culture held 9,781,190 shares, accounting for 2.94% of the company's total share capital, with shares obtained prior to the company's IPO and through capital reserve transfers [2][4]. Group 2: Reduction Plan Implementation Results - The reduction plan, disclosed on June 21, 2025, allowed Jingzhen Culture to reduce its holdings by up to 2,400,000 shares, representing no more than 0.7216% of the total share capital, with the reduction period set from July 14, 2025, to October 13, 2025 [3][6]. - As of the announcement date, Jingzhen Culture successfully reduced its holdings by 2,400,000 shares, which is exactly 0.7216% of the total share capital of 332,602,199 shares at the time of the plan disclosure [3][8].

Group 1 - Aladdin Biochemical Technology Co., Ltd. experienced a stock price increase of 5.18%, reaching 12.99 CNY per share, with a trading volume of 100 million CNY and a turnover rate of 2.37%, resulting in a total market capitalization of 4.321 billion CNY [1] - The company, established on March 16, 2009, and listed on October 26, 2020, focuses on the research, production, and sales of reagents, with its main revenue sources being research reagents (96.96%), laboratory consumables (2.15%), and other supplementary products (0.89%) [1] Group 2 - Morgan Stanley's fund, specifically the Morgan Stanley Yu Yue An He Mixed A Fund (009893), has a significant position in Aladdin, having increased its holdings by 59,700 shares in the second quarter, totaling 275,900 shares, which represents 5.24% of the fund's net value, making it the sixth-largest holding [2] - The Morgan Stanley Yu Yue An He Mixed A Fund was established on September 24, 2020, with a current size of 28.9066 million CNY, achieving a year-to-date return of 22.61% and a one-year return of 35.66%, ranking 4240 out of 8171 and 4277 out of 8004 in its category, respectively [2]

Group 1 - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., announced that part of the bank account funds of its subsidiary, Kasma Holdings Ltd., have been frozen due to a contractual dispute with Tianjin Rongda Weiye Technology Development Co., Ltd. [3][4] - The total amount frozen is 9,002,802.54 yuan, which represents 0.84% of the company's audited net assets as of December 31, 2024, and 0.87% of the net assets as of June 30, 2025. It also accounts for 1.93% of the company's audited cash and cash equivalents as of December 31, 2024, and 2.86% as of June 30, 2025. [2][4] - The company stated that the frozen funds constitute a small proportion of its cash resources and will not have a significant adverse impact on its production and operational activities. [2][4] Group 2 - The company is taking effective legal measures to resolve the dispute and aims to address the issue of the frozen account funds promptly, ensuring the protection of the company's and investors' legal rights. [5] - The company emphasizes that all information should be verified through its designated disclosure media, including Shanghai Securities News and Securities Times, as well as the Shanghai Stock Exchange website. [5]

Summary of Key Points Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns for the company and its shareholders [1][5]. Fundraising Overview - The company issued a total of 3.874 million convertible bonds at a face value of RMB 100 each, raising a total of RMB 387.4 million, with a net amount of RMB 373.38 million after deducting issuance costs of RMB 14.02 million [1][2]. Fund Management and Usage - All raised funds have been deposited into a special account, and the company has established a three-party and four-party supervision agreement with the sponsor and the bank [2][3]. - The company plans to invest up to RMB 150 million of the temporarily idle funds for cash management, ensuring that it does not affect the normal progress of fundraising investment projects [3][4]. Investment Strategy - The cash management will focus on low-risk investment products, and the company will ensure that the investment does not interfere with the ongoing projects [4][5]. - The board of directors has authorized the chairman to make investment decisions within the approved limits and timeframe [4][5]. Impact on Company - The cash management of idle funds is expected to improve fund utilization efficiency without affecting the company's main business operations, thereby potentially enhancing overall performance and returns for shareholders [4][5][6]. Compliance and Approval - The proposal for cash management has been approved by both the board of directors and the supervisory board, confirming compliance with relevant laws and regulations [5][6].

Group 1 - The company has approved participation in the auction for an 81.96% stake in Kasma Holdings, owned by the Chinese Academy of Sciences, through a board resolution [1] - The auction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1] - The company will sign a property transaction contract within five working days and pay the transaction price and service fees to the designated account [1] Group 2 - The transaction aims to broaden the company's product sales channels, enhance product development capabilities, integrate upstream and downstream resources, and improve market competitiveness and profitability [2]

Core Points - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., has maintained its credit rating for both the company and its convertible bonds at "A+" with a stable outlook [1][4] - The tracking credit rating was conducted by Zhongzheng Pengyuan Credit Rating Co., Ltd. and the results were published on June 24, 2025 [1][2] - The previous credit rating for the company and its bonds was also "A+" with a stable outlook, indicating consistency in the company's financial health [1][4] Summary by Sections - **Company Credit Rating**: The company's main credit rating remains "A+" with a stable outlook, reflecting its solid financial position [1][4] - **Bond Credit Rating**: The credit rating for the "Aladdin Convertible Bonds" is also maintained at "A+" with a stable outlook, indicating reliability for investors [1][4] - **Rating Agency**: The credit rating was performed by Zhongzheng Pengyuan, which conducted a comprehensive analysis of the company's operational status and related industry [1][4]

Core Viewpoint - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., is set to hold an investor briefing on June 30, 2025, to discuss its 2024 annual report and Q1 2025 results, allowing investors to engage and ask questions [2][3][4]. Group 1: Meeting Details - The investor briefing will take place on June 30, 2025, from 09:00 to 10:00 [5]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [5]. - The meeting will be conducted in an interactive online format, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can submit questions from June 23 to June 27, 2025, via the Roadshow Center website or through the company's email [2][4]. - The company will address commonly asked questions during the briefing [3][4]. - Key personnel participating in the meeting include the Chairman and General Manager, Xu Jiuzhen, and the Secretary of the Board, Zhao Xin'an [4]. Group 3: Contact Information - For inquiries, investors can contact the Securities Affairs Department at 021-50560989 or via email at aladdindmb@163.com [6]. - After the briefing, the main content and outcomes will be available on the Roadshow Center website [6].